For the 12 CIS patients that converted to RRMS during the study, multiple regression modeling of time to conversion resulted in a highly significant model (adjusted R2 0.81, p = 0.006) when including baseline CSF levels of CXCL1, CXCL10, CXCL13, and NFL, and number of T2 lesions at baseline). The gene discussed is CXCL13; the disease is in situ carcinoma.